ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för brequinar sodium. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

33 träffar

Bibliografisk träff 2021-01-08

Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.

Li Y, Yi L, Cheng S, Wang Y, Wang J, Sun J, Zhang Q, Xu X.

J Gen Virol · research support, non-u.s. gov't; journal article · DOI 10.1099/jgv.0.001534

Bibliografisk träff 2020-01-01

An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase.

M S, B P, Swaminathan P.

Curr Comput Aided Drug Des · journal article · DOI 10.2174/1573409915666190528114703

Bibliografisk träff 2020-01-01

Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.

Kadir MFA, Othman S, Nellore K.

Curr Pharm Biotechnol · journal article · DOI 10.2174/1389201021666200611113734

Bibliografisk träff 2018-11-17

Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.

Dorasamy MS, Ab A, Nellore K, Wong PF.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2018.11.010

Bibliografisk träff 2018-01-01

Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids · clinical trial, phase ii; multicenter study; journal article · DOI 10.1080/15257770.2018.1508692

Bibliografisk träff 2017-09-05

Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.

Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF.

J Cancer · research-article; journal article · DOI 10.7150/jca.14835

Bibliografisk träff 1998-08-01

Brequinar sodium and liver hemoperfusion in xenotransplantation.

Chastanet S, Cursio R, Gugenheim J, Baldini E, Chevallier A, Damais A, Charpentier B, Mouiel J.

Transplant Proc · journal article · DOI 10.1016/s0041-1345(98)00606-x

Bibliografisk träff 1998-01-01

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Burris HA, Raymond E, Awada A, Kuhn JG, O'Rourke TJ, Brentzel J, Lynch W, King SY, Brown TD, Von Hoff DD.

Invest New Drugs · clinical trial; clinical trial, phase i; journal article · DOI 10.1023/a:1016066529642

Bibliografisk träff 1996-04-01

Brequinar sodium.

Cramer DV.

Transplant Proc · review; journal article

Bibliografisk träff 1996-04-01

The impact of crystallinity on Brequinar sodium hygroscopicity.

Wu LS, Pang J, Hussain MA.

Pharm Dev Technol · journal article · DOI 10.3109/10837459609031417

Bibliografisk träff 1995-01-01

Brequinar sodium.

Cramer DV.

Pediatr Nephrol · review; journal article · DOI 10.1007/bf00867685

Bibliografisk träff 1993-02-01

Prolongation of allograft and xenograft survival with mycophenolate mofetil (RS-61443) and brequinar sodium (DUP-785).

Hullett DA, Kawamura T, Fujino Y, Allison AM, Sollinger HW.

Transplant Proc · journal article

Bibliografisk träff 1993-01-01

Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.

de Forni M, Chabot GG, Armand JP, Fontana X, Recondo G, Domenge C, Carde P, Barbu M, Gouyette A.

Eur J Cancer · clinical trial; clinical trial, phase i; journal article · DOI 10.1016/s0959-8049(05)80206-0

Bibliografisk träff 1992-07-01

Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.

Chen SF, Perrella FW, Behrens DL, Papp LM.

Cancer Res · journal article

Bibliografisk träff 1992-05-01

The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.

Löffler M.

Biochem Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/0006-2952(92)90188-o

Bibliografisk träff 1992-02-01

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.

Peters GJ, Kraal I, Pinedo HM.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.1992.46

Bibliografisk träff 1990-08-01

In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.

Peters GJ, Schwartsmann G, Nadal JC, Laurensse EJ, van Groeningen CJ, van der Vijgh WJ, Pinedo HM.

Cancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 1990-08-01

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Noe DA, Rowinsky EK, Shen HS, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS.

Cancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 1990-08-01

Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.

Chen SF, Papp LM, Ardecky RJ, Rao GV, Hesson DP, Forbes M, Dexter DL.

Biochem Pharmacol · journal article · DOI 10.1016/0006-2952(90)90305-5

Bibliografisk träff 1990-02-01

Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.

Braakhuis BJ, van Dongen GA, Peters GJ, van Walsum M, Snow GB.

Cancer Lett · journal article · DOI 10.1016/0304-3835(90)90149-r

Bibliografisk träff 1990-01-01

Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.

Dodion PF, Wagener T, Stoter G, Drozd A, Lev LM, Skovsgaard T, Renard J, Cavalli F.

Ann Oncol · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1093/oxfordjournals.annonc.a057680

Bibliografisk träff 1990-01-01

Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.

Peters GJ, Nadal JC, Laurensse EJ, de Kant E, Pinedo HM.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/0006-2952(90)90657-7

Bibliografisk träff 1990-01-01

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Schwartsmann G, Dodion P, Vermorken JB, ten Bokkel Huinink WW, Joggi J, Winograd B, Gall H, Simonetti G, van der Vijgh WJ, van Hennik MB.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/bf00686235

Bibliografisk träff 1989-12-01

Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.

Schwartsmann G, van der Vijgh WJ, van Hennik MB, Klein I, Vermorken JB, Dodion P, ten Bokkel Huinink WW, Joggi G, Gall H, Crespeigne N.

Eur J Cancer Clin Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/0277-5379(89)90334-9

Bibliografisk träff 1989-10-01

A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Bork E, Vest S, Hansen HH.

Eur J Cancer Clin Oncol · journal article · DOI 10.1016/0277-5379(89)90097-7

Bibliografisk träff 1989-08-01

Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).

Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.

Cancer Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article

Bibliografisk träff 1989-07-01

The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.

de Kant E, Pinedo HM, Laurensse E, Peters GJ.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/0304-3835(89)90019-0

Bibliografisk träff 1989-01-01

The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).

Peters GJ, Laurensse E, de Kant E, Nadal JC, Pinedo HM.

Adv Exp Med Biol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/978-1-4684-5676-9_55

Bibliografisk träff 1988-12-01

Pharmacokinetics of Brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid.

Schwartsmann G, van der Vijgh WJ, Klein I, van Groeningen CJ, Vermorken JB, Pinedo HM.

Eur J Cancer Clin Oncol · letter · DOI 10.1016/0277-5379(88)90106-x

Bibliografisk träff 1988-09-01

DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.

Schwartsmann G, Peters GJ, Laurensse E, de Waal FC, Loonen AH, Leyva A, Pinedo HM.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/0006-2952(88)90636-3